دورية
Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma
| العنوان: | Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma |
|---|---|
| المؤلفون: | Dave, Hema, Mai, Mimi, Terpilowski, Madeline, Toner, Keri, Stanojevic, Maja, Galligan, Morgan, Shibli, Abeer, Grant, Melanie, Lazarski, Christopher, Maglo, Philip Y, Zhang, Nan, Tanna, Jay, Ambinder, Richard F., Glenn, Martha, Hanley, Patrick, Bollard, Catherine M. |
| المصدر: | Blood; November 2020, Vol. 136 Issue: 1, Number 1 Supplement 1 p18-18, 1p |
| مستخلص: | Background:Hodgkin Lymphoma (HL) Reed Sternberg cells express tumor associated antigens (TAA) that are potential targets for cellular therapies. We recently demonstrated that TAA specific T cells (TAA-T) targeting WT1, PRAME and Survivin were safe and associated with prolonged time to progression in solid tumors (Hont JCO 2019). Hence, we evaluated whether TAA-T cells are safe and elicit anti-tumor effects in patients with relapsed/refractory (rel/ref) HL. We further evaluated the safety of Nivolumab following the TAA-T infusion and its effect on the persistence of the TAA-T cells in vivo. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2020-142422 |